Literature DB >> 20201811

Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.

Lara A Ray1, Pauline F Chin, Karen Miotto.   

Abstract

Naltrexone is an opioid receptor antagonist with established efficacy, albeit moderate, for the treatment of alcohol dependence. This manuscript provides a critical review of the literature on naltrexone as a pharmacotherapy for alcoholism by covering the following areas: (a) clinical findings from treatment studies; (b) pharmacokinetics and safety data; (c) medication compliance and persistence; and (d) neurobiological and biobehavioral mechanisms of action of naltrexone for the indication of alcohol dependence. This review will then focus on the emerging literature on naltrexone pharmacogenetics, which has the potential to identify responders on the basis of genetic variation and to use genetic tools to individualize the use of this medication. Limitations and future directions in the research and practice of naltrexone for alcoholism are also outlined.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20201811     DOI: 10.2174/187152710790966704

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  52 in total

1.  Mirtazapine to reduce methamphetamine use: a randomized controlled trial.

Authors:  Grant N Colfax; Glenn-Milo Santos; Moupali Das; Deirdre McDermott Santos; Tim Matheson; James Gasper; Steve Shoptaw; Eric Vittinghoff
Journal:  Arch Gen Psychiatry       Date:  2011-11

Review 2.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

3.  Age-dependent and strain-dependent influences of morphine on mouse social investigation behavior.

Authors:  Bruce C Kennedy; Jules B Panksepp; Jenny C Wong; Emily J Krause; Garet P Lahvis
Journal:  Behav Pharmacol       Date:  2011-04       Impact factor: 2.293

4.  Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.

Authors:  Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; Deirdre Santos; Tim Matheson; Grant Colfax; Steven L Batki
Journal:  Addiction       Date:  2017-08-29       Impact factor: 6.526

Review 5.  The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies.

Authors:  Anna Warden; Emma Erickson; Gizelle Robinson; R Adron Harris; R Dayne Mayfield
Journal:  Pharmacogenomics       Date:  2016-12-05       Impact factor: 2.533

6.  Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.

Authors:  Spencer Bujarski; James MacKillop; Lara A Ray
Journal:  Exp Clin Psychopharmacol       Date:  2012-03-19       Impact factor: 3.157

Review 7.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

8.  Naltrexone-induced Nicolau syndrome masquerading as cutaneous abscess.

Authors:  Daniel Perli; Catharine Martone; Alwyn Rapose
Journal:  BMJ Case Rep       Date:  2012-12-14

Review 9.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

10.  Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial.

Authors:  Robert Miranda; Lara Ray; Alexander Blanchard; Elizabeth K Reynolds; Peter M Monti; Thomas Chun; Alicia Justus; Robert M Swift; Jennifer Tidey; Chad J Gwaltney; Jason Ramirez
Journal:  Addict Biol       Date:  2013-03-13       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.